Table 3.

Biological and targeted synthetic DMARDs under experimental trials and in the preregistration phase for psoriatic arthritis

Name of biological DMARDs and/or synthetic small molecule DMARDs	Drug target	Phase of randomized controlled trial
Bimekizumab	IL-17A and IL-17F	III
Risankizumab	IL-23 (subunitp19)	III/awaiting approval (preregistration phase)
Netakimab/BCD-085	IL-17A	III
Tildrakizumab	IL-23	III/awaiting approval (preregistration phase)
Guselkumab	IL-23	III/awaiting approval (preregistration phase)
Filgotinib	JAK1 (selective)	III
Upadacitinib/ABT-494	JAK1 (selective)	III
Brepocitinib/PF-06700841	TYK2/JAK1	II
BMS-986165	TYK2 (selective)	II